|
ViiV Healthcare on Wednesday said it received marketing authorisation from the European Commission for Triumeq PD, a treament for children living with HIV ViiV Healthcare is a specialist HIV company with GSK PLC as a majority shareholder, alongside shareholders Pfizer Inc and Shionogi & Co Ltd. It said Triumeq PD is the first dispersible single tablet regimen containing dolutegravir for children living with HIV, hailing the authorisation as an ‘important step meet ViiV Healthcare‘
|
